Calcium carbonate, but not sevelamer, is associated with better outcomes in hemodialysis patients: Results from the French ARNOS study

Hemodialysis International

Volumn 15, Issue 4, 2011, Pages 485-492

  Jean, Guillaume ^a   Lataillade, Dominique ^b   Genet, Leslie ^c   Legrand, Eric ^d   Kuentz, François ^e   Moreau Gaudry, Xavier ^e   Fouque, Denis ^c  

^a Centre de Rein Artificiel de Tassin   (France)

^b Centre de Néphrologie du Mont Blanc   (France)

^c EDOUARD HERRIOT HOSPITAL   (France)

^d Centre Hospitaliser   (France)

^e AGDUC   (France)

Author keywords

Calcium; Hemodialysis; Mineral disorders; Phosphate binder; Survival

Indexed keywords

CALCIUM CARBONATE; SEVELAMER;

AGED; ARTICLE; FEMALE; FRANCE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERPHOSPHATEMIA; MAJOR CLINICAL STUDY; MALE; MINERAL METABOLISM; MORTALITY; OUTCOMES RESEARCH; PRESCRIPTION; PROSPECTIVE PAYMENT; SURVIVAL;

AGED; AGED, 80 AND OVER; ANTACIDS; CALCIUM CARBONATE; CHELATING AGENTS; DISEASE-FREE SURVIVAL; FEMALE; FRANCE; HUMANS; MALE; MIDDLE AGED; POLYAMINES; PROSPECTIVE STUDIES; RENAL DIALYSIS; SURVIVAL RATE;

EID: 80054886678     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2011.00575.x     Document Type: Article

References (31)

1. Tentori F, Blayney MJ, Albert JM, etal. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: The Dialysis Outcomes And Practice Patterns Study (DOPPS). Am J Kidney Dis. 2008; 52:519-530.
2. Block GA. Prevalence and clinical consequences of elevated ca×p product in hemodialysis patients. Clin Nephrol. 2000; 54:318-324.
3. Sturtevant JM, Hawley CM, Reiger K, etal. Efficacy and side-effect profile of sevelamer hydrochloride used in combination with conventional phosphate binders. Nephrology (Carlton). 2004; 9:406-413.
4. Young EW, Akiba T, Albert JM, etal. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes And Practice Patterns Study (DOPPS). Am J Kidney Dis. 2004; 44:34-38.
5. De Santo NG, Frangiosa A, Anastasio P, etal. Sevelamer worsens metabolic acidosis in hemodialysis patients. J Nephrol. 2006; 19(Suppl 9):S108-S114.
6. D'Haese PC, Spasovski GB, Sikole A, etal. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int. 2003; 63(Suppl 85):S73-S78.
7. Tonelli M, Pannu N, Manns B. Oral phosphate binders in patients with kidney failure. N Engl J Med. 2010; 362:1312-1324.
8. Sankar DN, Suetonia CP, Jonathan CC, Grahame JE, Giovanni FMS. Benefits and harms of phosphate binders in ckd: A systematic review of randomized controlled trials. Am J Kidney Dis. 2009; 54:619-637.
9. Jamal SA, Fitchett D, Lok CE, Mendelssohn DC, Tsuyuki RT. The effects of calcium-based versus non-calcium-based phosphate binders on mortality among patients with chronic kidney disease: A meta-analysis. Nephrol Dial Transplant. 2009; 24:3168-3174.
10. Isakova T, Gutierrez OM, Chang Y, etal. Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol. 2009; 20:388-396.
11. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004; 15:2208-2218.
12. Kalantar-Zadeh K, Kuwae N, Regidor DL, etal. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int. 2006; 70:771-780.
13. Pelletier S, Roth H, Bouchet JL, etal. [mineral and bone status in French maintenance hemodialysis patients: A comparison of June 2005 and June 2008]. Néphrol Ther. 2010; 6:11-20.
14. Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: The USRDS waves 1, 3, and 4 study. J Am Soc Nephrol. 2005; 16:1788-1793.
15. Gotch FA, Panlilio F, Sergeyeva O, etal. A kinetic model of inorganic phosphorus mass balance in hemodialysis therapy. Blood Purif. 2003; 21:51-57.
16. Jean G, Vanel T, Terrat JC, etal. Treating mineral metabolism disorders in patients undergoing long hemodialysis: A search for an optimal strategy. Hemodial Int. 2009; 13:526-532.
17. Borzecki AM, Lee A, Wang SW, Brenner L, Kazis LE. Survival in end stage renal disease: Calcium carbonate vs. sevelamer. J Clin Pharm Ther. 2007; 32:617-624.
18. Panichi V, Bigazzi R, Paoletti S, etal. Impact of calcium, phosphate, PTH abnormalities and management on mortality in hemodialysis: Results from the RISCAVID study. J Nephrol. 2010; 23:556-562.
19. Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int. 2007; 71:438-441.
20. Qunibi WY. Effects of sevelamer and calcium on coronary artery calcification in patients new to dialysis: Time for better controlled clinical trials. Kidney Int. 2006; 69:1093.
21. Suki WN, Zabaneh R, Cangiano JL, etal. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int. 2007; 72:1130-1137.
22. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002; 62:245-252.
23. Qunibi W, Moustafa M, Muenz LR, etal. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: The Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis. 2008; 51:952-965.
24. Kdigo C-M. Work Group Kdigo clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int. 2009; 76:S1-130.
25. London GM, Marchais SJ, Guerin AP, Boutouyrie P, Metivier F, de Vernejoul M-C. Association of bone activity, calcium load, aortic stiffness, and calcifications in ESRD. J Am Soc Nephrol. 2008; 19:1827-1835.
26. Ando R, Naito S, Inagaki Y, etal. The influence of dialysate calcium on the therapeutic effects of sevelamer hydrochloride in hemodialysis patients with secondary hyperparathyroidism under treatment of intravenous vitamin D metabolites. Ther Apher Dial. 2005; 9:16-23.
27. Qunibi W, Muenz LR. Progression of calcification in the calcium acetate renagel evaluation-2 (CARE-2) study. Am J Kidney Dis. 2008; 52:1022-1023. author reply 1023-1024.
28. Borras M, Marco MP, Fernandez E. Treatment with sevelamer decreases bicarbonate levels in peritoneal dialysis patients. Perit Dial Int. 2002; 22:737-738.
29. van Mierlo LA, Arends LR, Streppel MT, etal. Blood pressure response to calcium supplementation: A meta-analysis of randomized controlled trials. J Hum Hypertens. 2006; 20:571-580.
30. Weingarten MA, Zalmanovici A, Yaphe J. Dietary calcium supplementation for preventing colorectal cancer and adenomatous polyps. Cochrane Database Syst Rev. 2008; (1):CD003548.
31. Bischoff-Ferrari HA, Rees JR, Grau MV, Barry E, Gui J, Baron JA. Effect of calcium supplementation on fracture risk: A double-blind randomized controlled trial. Am J Clin Nutr. 2008; 87:1945-1951.